52
Participants
Start Date
March 31, 2007
Primary Completion Date
June 30, 2011
Study Completion Date
June 30, 2011
Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)
IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
Duke University Medical Center, Durham
Joe Arrington Cancer Research and Treatment Center, Lubbock
Fox Chase Cancer Center, Philadelphia
Lead Sponsor
Enzon Pharmaceuticals, Inc.
INDUSTRY